Company

OptiNose US, Inc.

OptiNose develops nasal drug delivery technology and specialty pharmaceutical products.

About

Founded in 2000 and based in Pennsylvania, OptiNose develops nasal drug delivery technology and treatments for conditions including migraine and chronic rhinitis. Its products include XHANCE and ONZETRA Xsail. The company went public on NASDAQ in 2017 under ticker OPTN, and Acorn Bioventures invested USD 50 million in November 2022.

3Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in